Texas’ Arch Manning started the season as a top Heisman Trophy contender. Texas A&M’s Marcel Reed is finishing it as one. The ...

Data from Phase 2 BESTOW trial demonstrated a favorable safety and tolerability profile, substantially reducing the metabolic, neurologic, and cardiovascular toxicities commonly associated with ...

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with ...

View source version on businesswire.com: https://www.businesswire.com/news/home/20251112188096/en/ The articles, information, and content displayed on this webpage ...

– FREEDOM-DM1 15 mg/kg cohort demonstrated the highest mean splicing correction reported to date in DM1 patients – – FREEDOM2-DM1 5 mg/kg cohort on track to readout in Q1 2026, with all patients ...

– Topline data for Phase 2 trials of ALTO-101 in CIAS expected 1Q 2026 and ALTO-300 in MDD expected mid-2026 – – Closed $50 million PIPE; strong cash position of $184.2 million as of October 31 ...

CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $524 million EC and U.S. FDA label updates for CARVYKTI ® to include overall survival benefit versus standard of care ...

Last term, Drexel University faculty members were recognized for their scholarly research and prolific academic and professional contributions. This update offers a snapshot of activity courtesy of ...

Aimco to Seek Shareholder Approval to Adopt Plan of Sale and Liquidation, Estimates Liquidating Distributions of Between $5.75 and $7.10 Per Share. DENVER, Nov. 10, 2025 /PRNewswire/ -- Apartment ...

A few highlights from Bishop Manogue's 48-26 win over Reed on Friday night. Bishop Manogue will play at Spanish Springs on Friday, Nov. 14 ...